News
South Africa's government has estimated that universities and science councils could lose about $107 million in U.S. research ...
CHENNAI: Gilead Sciences has achieved another milestone in its efforts to bring in a preventive drug to curb the still ...
EMA recommends Gilead Sciences' Lenacapavir for HIV prevention, with FDA approval and generic options available soon.
Researchers found that lenacapavir reduced almost 100% reduction new HIV infections among participants who received it as a ...
According to experts at the IAS 2025 meeting in Kigali, Rwanda, AI revolutionizes HIV vaccine development by enhancing design ...
Health Minister Aaron Motsoaledi urged urgent action and innovation as South Africa positions itself to lead the rollout of a ...
9h
The Observer on MSN‘Dark Age’ for HIV treatment as vaccine sceptic wields the axe
It was supposed to be a banner year in the fight against the HIV epidemic. Nationwide infection rates were gradually falling, ...
Decisions from the U.S. Preventative Services Task Force impact millions of people’s access to preventative care for cancer, ...
Despite the recent approval of lenacapavir as a twice yearly PrEP, there is still a need for choice in HIV prevention, argue ...
South Africa's government has estimated that universities and science councils could lose about $107 million in US research ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results